GH stock forecast
Our latest prediction for Guardant Health, Inc.'s stock price was made on the Sept. 11, 2019 when the stock price was at 76.50$.
In the short term (2weeks), GH's stock price should underperform the market by -0.04%. During that period the price should oscillate between -9.27% and +10.80%.
In the medium term (3months), GH's stock price should outperform the market by 1.38%. During that period the price should oscillate between -20.15% and +28.71%.Get email alerts
About Guardant Health, Inc.
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
At the moment the company generates 184M USD in revenues.
On its last earning announcement, the company reported a loss of -2.64$ per share.
The book value per share is 5.62$
Three months stock forecastSept. 11, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|